$IMTX News

Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile

Should Updated Trial Results Require Action From Immatics (IMTX) Investors?

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Immatics Announces $150 Million Underwritten Offering

Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

Immatics: PRAME Is Becoming More Than A Single-Asset Story

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Immatics Announces First Quarter 2026 Financial Results and Business Update

Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth